Industry Sessions

Industry Supported Symposia will be offered to conference attendees free of charge. These will be sponsored by a variety of companies. Topics have been approved by the Program Committee and are intended to complement the Plenary Sessions, Mini Symposia and Educational Sessions of the Conference.

Sunday, September 6

13:00 – 14:30 Symposium supported by Pfizer: Emergence of Biosimilars: Reflections on Their Potential Impact
  Room: 401 – 404
14:45 – 16:15 Symposium supported by Bristol-Myers Squibb: Great Debates in Lung Cancer: Integrating the New Paradigm of Immuno-Oncology into Non-Small Cell Lung Cancer Management
  Room: Colorado Convention Center, Mile High Ballroom 2 + 3
Webpage: www.bmli.com/live/debates/index.php
Target audience: The target audience for this symposium on Immuno-Oncology for NSCLC includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary approach and, thus, all of the aforementioned clinician specialties are invited to participate in this symposium.
16:30 – 18:00 Symposium supported by Genentech: Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
  Room: 601 + 603
Speakers: Chandra Belani, USA & Craig Reynolds, USA
   

Monday, September 7

07:00 – 08:00
Symposium supported by Helsinn Therapeutics, Inc.: Finding Solutions to Difficult Problems in Lung Cancer: Treatment of Cancer Cachexia*
  Room: Colorado Convention Center, Room 601 + 603
Agenda: link
Webpagewww.prIMEoncology.org/nsclc_cachexia_denver2015
Target audience: This educational activity is specifically designed for medical, radiation, and surgical oncologists and other healthcare professionals interested and/or involved in the treatment of cancer cachexia in patients with non-small cell lung cancer (NSCLC).
  Symposium supported by AstraZeneca: Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Questions*
  Room: Colorado Convention Center, Room 205 + 207
Agenda: link
Webpagewww.prIMEoncology.org/2015nsclcdenver
Target audience: This activity is designed to meet the needs of medical oncologists, surgical and radiation oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with NSCLC.
  Symposium supported by Biodesix: Blood-Based Biomarkers to Guide the Treatment of Advanced NSCLC*
  Room: Colorado Convention Center, Mile High Ballroom 2a – 3b
Speaker: Leora Horn, Vanderbilt-Ingram Cancer Center, USA
Description: For some time now, the oncology community has been seeking easily accessible, non-invasive methods to identify molecular alterations and biomarkers that characterize advanced cancer. Following tissue diagnosis for advanced lung cancer, there may be insufficient tissue for further molecular testing and another biopsy is not always feasible. Blood-based testing is evolving as a useful prognostic and predictive tool and may have the potential to measure emerging resistance prior to detection of progression on conventional imaging. This educational program will: • Review the unmet clinical needs across the continuum of care in non-small cell lung cancer (NSCLC) • Assess genomic and proteomic technologies being utilized to measure blood-based biomarkers that are prognostic, predictive, and useful for detecting emerging resistance prior to conventional imaging • Examine the analytic and clinical data associated with the current blood-based tests that exist across the continuum care in NSCLC (both genomic and proteomic biomarkers) • Introduce the challenges of tissue-based testing to predict response to immunotherapies • Introduce early phase development of blood-based tests to predict response to immunotherapies.
© Biodesix, Inc. 2015. ALL RIGHTS RESERVED.
  Symposium supported by Genentech: The PD-L1 Pathway in Cancer Immune Evasion*
  Room: 401 – 404
Speakers: Daniel Morgensztern, USA
10:00 – 10:30 Exhibit Showcase Session: Lilly: Metastatic Non-Small Cell Lung Cancer (NSCLC) Promotional Presentation
© Lilly USA, LLC 2015. ALL RIGHTS RESERVED.
  Room: Colorado Convention Center, Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)
Speaker: Dr. Ronald Scheff, USA
Description: This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, and/or VT, a Veterans Affairs employee, and/or a state government employee, you may be restricted from accepting industry-provided food/beverage [and/or educational item(s)]. Please consult your state or federal regulations or ethics laws. This program is intended only for invited healthcare professionals (HCPs) or other appropriate personnel for whom the information that is being presented will be relative to their practice. We regret that spouses or other guests cannot be accommodated.
© Lilly USA, LLC 2015. ALL RIGHTS RESERVED.
12:30 – 14:00 Symposium supported by Lilly: Beyond The Guidelines – Management of Patients with Non-Small Cell Lung Cancer without Targetable Tumor Mutations
  Room: Colorado Convention Center, Plenary Hall (Bellco Theater)
Webpagewww.researchtopractice.com/Meetings/IASLC2015/NSCLC
16:00 – 16:30 Exhibit Showcase Session: Lilly: Challenges with Squamous Non-Small Cell Lung Cancer (NSCLC)
  Room: Colorado Convention Center, Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)
18:30 – 20:00 Symposium supported by Clovis Oncology: Critical Insights on Mutant-Specific Epidermal Growth Factor Receptor Inhibitors for NSCLC
  Room: Colorado Convention Center, Room 601 + 603
Webpage: www.ecgcme.com/T790M
  *Concurrent Sessions 

Tuesday, September 8

07:00 – 08:00 Symposium supported by Myriad: Improving the Care of Patients with Early-Stage Lung Adenocarcinoma: Role of Prognostic Signatures*
  Room: Colorado Convention Center, Room 201 + 203
  Symposium supported by Celgene: The New Frontier in NSCLC – Beyond EGFR, VEGF and ALK: Expanding the Paradigm to Include Patients Without Actionable mutations – CRITICAL QUESTIONS and CASE BASED LEARNING*
  Room: Colorado Convention Center, Mile High Ballroom 2 + 3
Webpage: www.bmli.com/live/nsclc/index.php
Target audience: The target audience for this symposium on managing NSCLC patients without actionable mutations includes medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied health-care professionals involved in the treatment, care and management of patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary approach and, thus, all of the aforementioned clinician specialties are invited to participate in this symposium.
  Symposium supported by Pfizer: Recent Advancements in the Identication and Treatment of ALK+ Metastatic NSCLC*
  Room: 401 – 404
09:50 – 10:40 Exhibit Showcase Session: Lilly: Shared Voice – Individualizing Patient – Centered Communication for Advanced Lung Cancer Patients
  Room: Colorado Convention Center, Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)
12:30 – 13:00 Exhibit Showcase Session by Guardant Health: Guardant Health: Guardant360: Clinical Impact of Biopsy-Free Tumor Sequencing in NSCLC
  Room: Colorado Convention Center, Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)
12:30 – 14:00 Symposium supported by Merck: Debates and Controversies: Immuno-Oncology in Advanced NSCLC
  Room: Colorado Convention Center, Plenary Hall (Bellco Theater)
Webpagemedscape.org/townhall/io-nsclc
  Room: Colorado Convention Center, Exhibit Showcase Theater in the Exhibit Hall (Halls B + C)
18:30 – 20:00 Symposium supported by Boehringer Ingelheim: Individual EGFR Mutations: Informing First-Line Treatment in EGFR Mutation-Positive NSCLC
  Room: Colorado Convention Center, Room 205 + 207
Agenda: Click here
  *Concurrent Sessions

Wednesday, September 9

07:00 – 08:00 Symposium supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Genentech BioOncology: The Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer*
  Room: Colorado Convention Center, Room 401 – 404
Webpagewww.researchtopractice.com/Meetings/IASLC2015/Immunotherapy
  Symposium supported by Boehringer Ingelheim Pharmaceuticals, Inc.: ERBB Family Blockade in NSCLC: Expert Perspectives on Optimizing Management*
  Room: Colorado Convention Center, Room 601 + 603
Webpage: www.ecgcme.com/wclc15-erbb
12:30 – 14:00 Symposium supported by Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Foundation Medicine, Genentech BioOncology and Novartis Pharmaceuticals Corporation: Targeted Treatment of Non-Small Cell Lung Cancer: Current Algorithms and New Agents
  Room: Colorado Convention Center, Plenary Hall (Bellco Theater)
Webpagewww.researchtopractice.com/Meetings/IASLC2015/Mutations
  *Concurrent Sessions
WCLC 2015 UPDATES